Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis - Top-Institutions - MDSpire

Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis

  • By

  • Asad Omarion

  • Yaman Ayasa

  • Zainab Omarion

  • Batoul Jayouse

  • Hazem Ayesh

  • July 3, 2026

  • 0 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Endocrinology

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Endocrinology

  • #3

    University of Adelaide
    University of Adelaide

    Adelaide, South Australia

    Key Differentiators

    • Endocrinology

  • #4

    Texas Tech University Health Sciences Center El Paso
    Texas Tech University Health Sciences Center El Paso

    El Paso, Texas

    Key Differentiators

    • Endocrinology

  • #5

    UK Biobank
    UK Biobank

    Manchester, England

    Key Differentiators

    • Endocrinology

Original Source(s)

Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis

  • by Asad Omarion, Yaman Ayasa, Zainab Omarion, Batoul Jayouse, Hazem Ayesh

  • July 3, 2026

Related Content

Non-linear saturation threshold of gonadotropin dose on cumulative live birth rates in advanced-age women with polycystic ovary syndrome: a retrospective cohort study

Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study

PCOS Renamed PMOS After Global Consensus

International initiative reframes a common endocrine disorder around its metabolic and ovarian features rather than ovarian cysts